Cryoglobulinemia pathophysiology: Difference between revisions

Jump to navigation Jump to search
No edit summary
No edit summary
Line 9: Line 9:


=== Type I cryoglobulinemia (Monoclonal immunoglobulin) ===
=== Type I cryoglobulinemia (Monoclonal immunoglobulin) ===
'''Key background associations'''
 
==== '''Key background associations''' ====
* Type I cryglobulinemia is usually seen in patients suffering from disorders of lymphoproliferation such as:
* Type I cryglobulinemia is usually seen in patients suffering from disorders of lymphoproliferation such as:
** Multiple myeloma (MM)
** Multiple myeloma (MM)
Line 15: Line 16:
** Waldenstrom's macroglobulinemia
** Waldenstrom's macroglobulinemia
** Chronic lymphocytic leukemia (CLL)
** Chronic lymphocytic leukemia (CLL)
'''Chronic immune stimulation'''
 
==== Mechanisms leading to precipitation of immunoglobulins (Ig) ====
'''(a) Chronic immune stimulation'''
* The lymphoproliferative and hematological disorders listed above lead to chronic activation of the immune system and production of higher concentrations of monoclonal immunoglobulins (usually IgG or IgM) at temperatures below 37 degrees celcius.
* The lymphoproliferative and hematological disorders listed above lead to chronic activation of the immune system and production of higher concentrations of monoclonal immunoglobulins (usually IgG or IgM) at temperatures below 37 degrees celcius.
'''Aggregation of immunoglobulins'''
'''(b) Aggregation of immunoglobulins'''
* Self aggregation through Fc fragment of immunoglobulins is the proposed mechanism of production of cryoglobulins in type I cryoglobulinemia
* Self aggregation through Fc fragment of immunoglobulins is the proposed mechanism of production of cryoglobulins in type I cryoglobulinemia
'''Modification of Ig heavy (H) and light (L) chains'''
'''(i) Modification of Ig heavy (H) and light (L) chains'''
 
*
'''Reduced concentration of sialic acid'''
'''(ii) Reduced concentration of sialic acid'''


'''Deficiency of galactose in the Fc portion of the Ig'''
'''(iii) Deficiency of galactose in the Fc portion of the Ig'''


'''Somatic Ig mutations'''
'''(iv) Somatic Ig mutations'''


'''Non-specific Fc–Fc interactions'''
'''(v) Non-specific Fc–Fc interactions'''


It is important to note that these two different, yet highly representative, clinical syndromes generally reflect different types of underlying CG:
It is important to note that these two different, yet highly representative, clinical syndromes generally reflect different types of underlying CG:

Revision as of 15:59, 1 May 2018

Cryoglobulinemia Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Cryoglobulinemia from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X Ray

CT

MRI

Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Cryoglobulinemia pathophysiology On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Cryoglobulinemia pathophysiology

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Cryoglobulinemia pathophysiology

CDC on Cryoglobulinemia pathophysiology

Cryoglobulinemia pathophysiology in the news

Blogs on Cryoglobulinemia pathophysiology

Directions to Hospitals Treating Cryoglobulinemia

Risk calculators and risk factors for Cryoglobulinemia pathophysiology

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor-In-Chief: Cafer Zorkun, M.D., Ph.D. [2]

Overview

Pathophysiology

Cryoglobulins are proteins (single or mixed immunoglobulins) that precipitate from serum and plasma when cooled. They are produced due to chronic immune system activation and lypmphoproliferation. Cryoglobulins have a tendency to redissolve on rewarming. The pathogenesis of cryoglobulinemia differs slightly based on the type of disorder and disease associations. The following are the major mechanisms involved in the pathogenesis of cryoglobulinemia:

Type I cryoglobulinemia (Monoclonal immunoglobulin)

Key background associations

  • Type I cryglobulinemia is usually seen in patients suffering from disorders of lymphoproliferation such as:
    • Multiple myeloma (MM)
    • Monoclonal gammopathy of undetermined significance (MGUS)
    • Waldenstrom's macroglobulinemia
    • Chronic lymphocytic leukemia (CLL)

Mechanisms leading to precipitation of immunoglobulins (Ig)

(a) Chronic immune stimulation

  • The lymphoproliferative and hematological disorders listed above lead to chronic activation of the immune system and production of higher concentrations of monoclonal immunoglobulins (usually IgG or IgM) at temperatures below 37 degrees celcius.

(b) Aggregation of immunoglobulins

  • Self aggregation through Fc fragment of immunoglobulins is the proposed mechanism of production of cryoglobulins in type I cryoglobulinemia

(i) Modification of Ig heavy (H) and light (L) chains

(ii) Reduced concentration of sialic acid

(iii) Deficiency of galactose in the Fc portion of the Ig

(iv) Somatic Ig mutations

(v) Non-specific Fc–Fc interactions

It is important to note that these two different, yet highly representative, clinical syndromes generally reflect different types of underlying CG:

  1. Hyperviscosity is typically associated with CG due to hematological malignancies and monoclonal immunoglobulins.
  2. "Meltzer's triad" of palpable purpura, arthralgia and myalgia is generally seen with polyclonal CGs seen in essential-, viral-, or connective tissue disease-associated CG.
  • MC is closely associated with hepatitis C infection and is thought to activate B lymphocytes by binding to CD81.
  • 80-95% of patients with MC have circulating anti-HCV antibodies or circulating HCV RNA in the serum or within the cryoprecipitate.
  • Polyclonal IgG anti-HCV have been noted in the cryoprecipitate as well.
  • Approximately 50% of patients with chronic hepatitis C and 15% with hepatitis B will have circulating MC (1/2 Type II, 2/3 Type III).
  • It is unclear what the antigen trigger is for production of the MC, but it is though that the hepatitis C viral RNA itself may be the factor since it is found in high quantities in the cryoprecipitate.

References


Template:WikiDoc Sources